Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › VIMTALABS

VIMTALABS

Vimta Labs Limited
Micro-capPharma ↗

What the six lenses say about VIMTALABS — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹640.6
2026-09-08
VWAP · 1Y anchor
₹684
-6.3% from VWAP
P/E · TTM
23.2×
TTM EPS ₹27.6
52-week range
52%
position low→high
RSI(14)
55
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How VIMTALABS’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
8.5
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD890›

The actual numbers

Price vs VWAP (1y)-6.3%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+16.1%
Price vs 50-EMA+6.1%
RSI(14)55
RS vs Nifty 500 · 3M+17.1%
RS vs sector · 3M+11.1%
52-week range52%
Volume vs 30d avg0.67×
Volume vs 60d avg0.42×
ATR(14) · volatility27.0
Bollinger width · vol contraction0.085
FundamentalD857›

The actual numbers

Return on equity (ROE)17.9%
Operating margin24.0%
Net margin18.3%
Revenue growth · YoY+4.9%
EPS growth · YoY+48.2%
Debt / equity0.04×

Full 8-quarter history in the financials table below.

ValuationD749›

The actual numbers

P/E (TTM)23.2×
TTM EPS₹27.6
52-week range52%
CatalystD537›

The actual numbers

Earnings & momentum34
Capital actions18
Governance86

Every filing in the corporate-announcements panel below.

FlowD960›

The actual numbers

Promoter holding35.9%
Delivery · 30d avg40.5%
Up/down-day asymmetry-1.3pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D8 + D9 ) ÷ 2 = 8.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
87
Conviction score 87/100 · avg-decile strength 8.5/10
Conviction score87/100›
TechnicalD8›
FundamentalD8›
ValuationD7›
CatalystD5›
FlowD9›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+1.3pp
+0.8pp
+3.3pp
+18.7pp
+50.9pp
-19.1pp
Nifty 500
Broad-market baseline
+1.2pp
+0.8pp
+2.2pp
+17.1pp
+45.1pp
-24.4pp
Sector
Own-sector index
—
—
-0.6pp
+11.1pp
+32.0pp
-45.2pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

VIMTALABS daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
640.65+5.00

Relative strength

RS vs baseline · rebased to 100

VIMTALABS ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
192.60+2.31

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricMar '23Jun '23Sep '23Dec '23Mar '24Jun '24Sep '24Dec '24
Revenue (₹cr)8283738280828590
↳ change QoQ—+2.0%-12.1%+11.3%-2.4%+2.6%+3.7%+6.1%
EBITDA (₹cr)2525182325253134
EBITDA margin30.4%30.2%24.4%27.8%31.3%30.8%36.1%38.1%
PAT (₹cr)131261012121521
↳ change QoQ—-3.8%-48.1%+60.1%+21.9%-0.6%+24.2%+41.0%
Net margin15.5%14.6%8.6%12.4%15.5%15.0%18.0%23.9%
EPS (₹)5.735.512.854.575.585.546.889.65
D/E————————
YoY growth · Dec '24Revenue +10.1% YoYPAT +112.2% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 8 Sep '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 2 Sep '26
    MEDIUMcapital
    Credit Rating
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 31 Aug '26
    LOWgovernance
    Spurt in Volume
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Aug '26
    LOWgovernance
    Spurt in Volume
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 21 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 28 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 28 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 24 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 20 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 20 Jul '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 20 Jul '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 20 Jul '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 15 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds VIMTALABS

Mutual funds holding VIMTALABS (1)

FundWeightAUM ₹crGrade
WhiteOak Capital Phrm and Hlthcr Reg Gr0.76%825

ETFs holding VIMTALABS (0)

No tracked ETF holds VIMTALABS ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma